1 Howell A,Anderson AS,Clarke RB,et al.Risk determination and prevention of breast cancer[J].Breast Cancer Res,2014,16(5):446.
2 Rahib L,Smith BD,Aizenberg R,et al.Projecting cancer incidence and deaths to 2030:the unexpected burden of thyroid,liver,and pancreas cancers in the United States[J].Cancer Res,2014,74(11):2913-2921.
3 Muscella A,Greco S,Elia MG,et al.Angiotensin II stimulation of Na+/K+ATPase activity and cell growth by calcium-independent pathway in MCF-7 breast cancer cells[J].Endocrinol,2002,173(2):315-23.
4 Clere N,Corre I,Faure S,et al.Deficiency or blockade of angiotensin II type 2 receptor delays tumorigenesis by inhibiting malignant cell proliferation and angiogenesis[J].Int J Cancer,2010,127(10):2279-2291.
5 Naffah-Mazzacoratti MG,Gouveia TL,Simes PS,et al.What have we learned about the kallikrein-kinin and renin-angiotensin systems in neurological disorders?[J].World J Biol Chem,2014,5(2):130-140.
6 Yu C,Tang W,Wang Y,et al.Downregulation of ACE2/Ang-(1-7)/Mas axis promotes breast cancer metastasis by enhancing store-operated calcium entry[J].Cancer Lett,2016,376(2):268-277.
7 Moreno-Muoz D,Haba-Rodríguez JR,Conde F,et al.Genetic variants in the renin-angiotensin system predict response to bevacizumab in cancer patients[J].Eur J Clin Invest,2015,45(12):1325-1332.
8 Luo Y,Tanabe E,Kitayoshi M,et al.Expression of MAS1 in breast cancer[J].Cancer Sci,2015,106(9):1240-1248.
9 Chen X,Meng Q,Zhao Y,et al.Angiotensin II type 1 receptor antagonists inhibit cell proliferation and angiogenesis in breast cancer[J].Cancer Lett,2013,328(2):318-324.
10 Rodrigues-Ferreira S,Abdelkarim M,Dillenburg-Pilla P,et al.Angiotensin II facilitates breast cancer cell migration and metastasis[J].PLoS One,2012,7(4):e35667.
11 Herr D,Rodewald M,Fraser HM,et al.Potential role of renin-angiotensin-system for tumor angiogenesis in receptor negative breast cancer[J].Gynecol Oncol,2008,109(3):418-425.
12 Arrieta O,Pineda-Olvera B,Guevara-Salazar P,et al.Expression of AT1 and AT2 angiotensin receptors in astrocytomas is associated with poor prognosis[J].Br J Cancer,2008,99(1):160-166.
13 Zhao Y,Chen X,Cai L,et al.Angiotensin II/angiotensin II type I receptor(AT1R)signaling promotes MCF‐7 breast cancer cells survival via PI3‐kinase/Akt pathway[J].J Cell Physiol,2010,225(1):168-173.
14 Du N,Feng J,Hu LJ,et al.Angiotensin II receptor type 1 blockers suppress the cell proliferation effects of angiotensin II in breast cancer cells by inhibiting AT1R signaling[J].Oncol Rep,2012,27(6):1893-1903.
15 Oh E,Kim JY,Cho Y,et al.Overexpression of angiotensin II type 1 receptor in breast cancer cells induces epithelial-mesenchymal transition and promotes tumor growth and angiogenesis[J].Biochim Biophys Acta,2016,1863(6):1071-1081.
16 Arrieta O,Villarreal-Garza C,Vizcaíno G,et al.Association between AT1 and AT2 angiotensin II receptor expression with cell proliferation and angiogenesis in operable breast cancer[J].Tumour Biol,2015,36(7):5627-5634.
17 Fujita M,Hayashi I,Yamashina S,et al.Angiotensin type 1a receptor signaling-dependent induction of vascular endothelial growth factor in stroma is relevant to tumor-associated angiogenesis and tumor growth[J].Carcinogenesis,2005,26(2):271-279.
18 Egami K,Murohara T,Shimada T,et al.Role of host angiotensin II type 1 receptor in tumor angiogenesis and growth[J].Clin Invest,2003,112(1):67-75.
19 Imai N,Hashimoto T,Kihara M,et al.Roles for host and tumor angiotensin II type 1 receptor in tumor growth and tumor-associated angiogenesis[J].Lab Invest,2007,87(2):189-198.
20 De Paepe B,Verstraeten VL,De Potter CR,et al.Increased angiotensin II type-2 receptor density in hyperplasia,DCIS and invasive carcinoma of the breast is paralleled with increased iNOS expression[J].Histochem Cell Biol,2002,117(1):13-19.
21 Tahmasebi M,Barker S,Puddefoot JR,et al.Localisation of renin-angiotensin system(RAS)components in breast[J].Br J Cancer,2006,95(1):67-74.
22 Muscella A,Greco S,Elia MG,et al.Angiotensin II stimulation of Na⁺/K⁺ ATPase activity and cell growth by calcium-independent pathway in MCF-7 breast cancer cells[J].J Endocrinol,2002,173(2):315-323.
23 Molina A,Rodrigues-Ferreira S,Di Tommaso A,et al.ATIP,a novel superfamily of microtubule-associated proteins[J].Med Sci,2011,27(3):244-246.
24 Rodrigues-Ferreira S,Di Tommaso A,Dimitrov A,et al.8p22 MTUS1 gene product ATIP3 is a novel anti-mitotic protein underexpressed in invasive breast carcinoma of poor prognosis[J].PLoS One,2009,4(10):e7239.
25 Zuern C,Heimrich J,Kaufmann R,et al.Down-regulation of MTUS1 in human colon tumors[J].Oncol Rep,2010,23(1):183-189.
26 Xiao J,Chen JX,Zhu YP,et al.Reduced expression of MTUS1 mRNA is correlated with poor prognosis in bladder cancer[J].Oncol Lett,2012,4(1):113-118.
27 Passos-Silva DG,Verano-Braga T,Santos RA.Angiotensin-(1-7):beyond the cardio-renal actions[J].Clin Sci,2013,124(7):443-456.
28 Chochieva AR,Bolieva LZ,Dzhioev FK.New approaches to the drug prophylaxis of mammary tumor:evaluation of the prophylactic effect of lovastatin and captopril in rats with experimental mammary gland tumors[J].Eksp Klin Farmakol,2007,71(1):43-45.
29 Bader M,Santos RA,Unger T,et al.New therapeutic pathways in the RAS[J].J Renin Angiotensin Aldosterone Syst,2012,13(4):505-508.
30 Sipahi I,Debanne SM,Rowland DY,et al.Angiotensin-receptor blockade and risk of cancer:meta-analysis of randomised controlled trials[J].Lancet Oncol,2010,11(7):627-636.
31 Azoulay L,Assimes TL,Yin H,et al.Long-term use of angiotensin receptor blockers and the risk of cancer[J].PLoS One,2012,7(12):e50893.
32 Fryzek JP,Poulsen AH,Lipworth L,et al.A cohort study of antihypertensive medication use and breast cancer among Danish women[J].Breast Cancer Res Treat,2006,97(3):23-236.
33 Srensen GV,Ganz PA,Cole SW,et al.Use of β-blockers,angiotensin-converting enzyme inhibitors,angiotensin II receptor blockers,and risk of breast cancer recurrence:a Danish nationwide prospective cohort study[J].J Clin Oncol,2013,31(18):2265-2272.
34 Cardwell CR,Mc Menamin C,Hicks BM,et al.Drugs affecting the renin-angiotensin system and survival from cancer:a population based study of breast,colorectal and prostate cancer patient cohorts[J].BMC Med,2014,12(1):28.
35 Rice AS,Dworkin RH,McCarthy TD,et al.EMA401,an orally administered highly selective angiotensin II type 2 receptor antagonist,as a novel treatment for postherpetic neuralgia:a randomised,double-blind,placebo-controlled phase 2 clinical trial[J].Lancet,2014,383(9929):1637-1647.
36 McCarthy CA,Widdop RE,Denton KM,et al.Update on the angiotensin AT2 receptor[J].Curr Hypertens Rep,2013,15(1):25-30.
37 Wagenaar GTM,Laghmani EH,Fidder M,et al.Agonists of MAS oncogene and angiotensin II type 2 receptors attenuate cardiopulmonary disease in rats with neonatal hyperoxia-induced lung injury[J].Am J Physiol Lung Cell Mol Physiol,2013,305(5):340-351.
38 Petty WJ,Miller AA,McCoy TP,et al.Phase I and pharmacokinetic study of angiotensin-(1-7),an endogenous antiangiogenic hormone[J].Clin Cancer Res,2009,15(23):7398-7404.
39 Rodgers KE,Oliver J.Phase Ⅰ/Ⅱ dose escalation study of angiotensin 1-7[A(1-7)]administered before and after chemotherapy in patients with newly diagnosed breast cancer[J].Cancer Chemother Pharmacol,2006,57(5):559-568.
40 Ferreira AJ,Bader M,Santos RA.Therapeutic targeting of the angiotensin-converting enzyme 2/Angiotensin-(1-7)/Mas cascade in the renin-angiotensin system:a patent review[J].Expert Opin Ther Pat,2012,22(5):567-574.
41 Gallagher PE,Arter AL,Deng G,et al.Angiotensin-(1-7):a peptide hormone with anti-cancer activity[J].Curr Med Chem,2014,21(21):2417-2423.
42 Diop-Frimpong B,Chauhan VP,Krane S,et al.Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors[J].Proc Natl Acad Sci U S A,2011,108(7):2909-2914.
43 Iwai M,Nakaoka H,Senba I,et al.Possible involvement of angiotensin-converting enzyme 2 and Mas activation in inhibitory effects of angiotensin II Type 1 receptor blockade on vascular remodeling[J].Hypertension,2012,60(1):137-144.
44 Thakur A,Witteles RM.Cancer therapy-induced left ventricular dysfunction:interventions and prognosis[J].J Card Fail,2014,20(3):155-158.
45 Pham H,Schwartz BM,Delmore JE,et al.Pharmacodynamic stimulation of thrombogenesis by angiotensin(1-7)in recurrent ovarian cancer patients receiving gemcitabine and platinum-based chemotherapy[J].Cancer Chemother Pharmacol,2013,71(4):965-972.